ARTICLE | Company News
WARF, Cellectar deal
March 17, 2017 5:41 PM UTC
The foundation granted Cellectar rights to IP covering the method of use for Cellectar's CLR 131 to treat multiple myeloma (MM). As a result of the deal, the company gains remaining rights to exclusiv...
BCIQ Target Profiles